Abstract：
In this study, the European Academy of Dermatology and Venereology (EADV) Task Forces on Quality of Life and Patient-Oriented Outcomes and Urticaria and Angioedema has examined the Health-Related Quality of Life (HRQoL) measurement in the treatment of urticaria. The Dermatology Life Quality Index was the most frequently used HRQoL instrument in clinical trials on urticaria. Many reports of clinical trials of urticaria gave no exact numeric results related to HRQoL changes, making clear conclusions and comparisons with other studies impossible. The interpretation of HRQoL impairment data is more difficult when assessed by instruments without severity stratification systems. The minimal clinically significant difference (MCID) is a more clinically oriented and relevant parameter than depending on statistically significant changes in HRQoL scores. Therefore, using HRQoL instruments with established MCID data in clinical trials and clinical practice is preferred.
摘要：
在这项研究中,欧洲皮肤病和性病学会(EADV)生活质量和以患者为导向的结果以及荨麻疹和血管性水肿工作组检查了荨麻疹治疗中与健康相关的生活质量(QoHRL)测量结果.皮肤病学生活质量指数是荨麻疹临床试验中最常用的HRQoL工具。许多荨麻疹的临床试验报告没有给出与HRQoL变化相关的确切数字结果，不可能得出明确的结论并与其他研究进行比较。当通过没有严重程度分层系统的仪器进行评估时，对HRQoL损害数据的解释更加困难。与取决于HRQoL评分的统计学显着变化相比，最小临床显着差异（MCID）是更具临床针对性和相关性的参数。因此,在临床试验和临床实践中使用具有已建立的MCID数据的HRQoL仪器是首选。
